Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-02-20

Clinical Trial Update: CC-5013 With or Without Dexamethasone in Treating Patients With Primary Systemic Amyloidosis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating lenalidomide (CC-5013) with or without dexamethasone for AL amyloidosis; results were posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • DEXAMETHASONE (Dexamethasone)
  • Lenalidomide (lenalidomide)

Snippet

Sponsor: Vaishali Sanchorawala | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2017-02-20